Ocular toxicity (keratopathy, blurred vision)
Eye problems from cancer drugs: blurred vision and corneal damage from certain ADCs (belantamab, tisotumab), retinal fluid from MEK inhibitors, and inflammation from immunotherapy. Usually reversible with dose holds, but they need regular eye examinations.
ADCs with MMAF or other non-cleavable tubulin payloads (belantamab mafodotin) and tissue factor ADCs (tisotumab vedotin) cause keratopathy in most patients because payload reaches the corneal epithelium, requiring ophthalmology checks before each dose, lubricating drops and dose modification, and prompting the REMS programme and dose reductions that followed belantamab's re-approval. MEK inhibitors cause transient serous retinopathy, EGFR inhibitors cause conjunctivitis and trichomegaly, and checkpoint inhibitors cause uveitis. Ocular toxicity has ended some ADC programmes and is a key design consideration for payload and linker choice.
Pages like this
not linked directly; found by shared links- TermMMAF
Shares Belantamab mafodotin, Tubulin inhibitor payloads, Antibody-drug conjugate (ADC).
- TermHyperglycaemia (PI3K/AKT inhibitor class effect)
Shares Therapeutic index (therapeutic window), Dose reduction, interruption and discontinuation.
- TermMaleimidocaproyl (mc), non-cleavable
- TermPharmacokinetics (PK), half-life and exposure
Shares Therapeutic index (therapeutic window), Dose reduction, interruption and discontinuation.
- TermProject Optimus
Shares Therapeutic index (therapeutic window), Dose reduction, interruption and discontinuation, Antibody-drug conjugate (ADC).
- TermMaximum tolerated dose (MTD)
Shares Therapeutic index (therapeutic window), Dose reduction, interruption and discontinuation.
- TermDM1
Shares Tubulin inhibitor payloads, Antibody-drug conjugate (ADC).
- TermDM4
Shares Tubulin inhibitor payloads, Antibody-drug conjugate (ADC).